BSE:532660

Stock Analysis Report

Executive Summary

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells specialty chemicals, dyes, and pharmaceutical ingredients in India, Mexico, Spain, and Hungary.

Snowflake

Fundamentals

Average dividend payer and fair value.

Risks

  • Vivimed Labs has significant price volatility in the past 3 months.
  • Vivimed Labs is not covered by any analysts.

Share Price & News

How has Vivimed Labs's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-6.9%

BSE:532660

-0.2%

IN Pharmaceuticals

-2.1%

IN Market


1 Year Return

-78.6%

BSE:532660

-24.2%

IN Pharmaceuticals

-14.7%

IN Market

532660 underperformed the Pharmaceuticals industry which returned -24.1% over the past year.

532660 underperformed the Market in India which returned -14.6% over the past year.


Share holder returns

532660IndustryMarket
7 Day-6.9%-0.2%-2.1%
30 Day-4.2%-2.8%-3.9%
90 Day-33.0%-6.9%-10.1%
1 Year-78.4%-78.6%-23.5%-24.2%-12.9%-14.7%
3 Year-79.5%-79.7%-24.3%-25.9%17.7%11.5%
5 Year-76.0%-76.4%-6.8%-9.7%35.4%22.5%

Price Volatility Vs. Market

How volatile is Vivimed Labs's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Vivimed Labs undervalued based on future cash flows and its price relative to the stock market?

3.17x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Vivimed Labs's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Vivimed Labs's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Vivimed Labs is good value based on earnings compared to the IN Pharmaceuticals industry average.

Vivimed Labs is good value based on earnings compared to the India market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Vivimed Labs, we can't assess if its growth is good value.


Price Based on Value of Assets

Vivimed Labs is good value based on assets compared to the IN Pharmaceuticals industry average.


Next Steps

Future Growth

How is Vivimed Labs expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

21.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Vivimed Labs is high growth as no revenue estimate data is available.

Vivimed Labs's earnings are expected to grow significantly at over 20% yearly.

Unable to compare Vivimed Labs's revenue growth to the India market average as no estimate data is available.

Vivimed Labs's earnings growth is expected to exceed the India market average.

Vivimed Labs's earnings growth is expected to exceed the low risk savings rate of 7.6%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Vivimed Labs will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Vivimed Labs performed over the past 5 years?

4.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Vivimed Labs's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.

Vivimed Labs's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Vivimed Labs's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.


Return on Equity

Vivimed Labs has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Vivimed Labs used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

Vivimed Labs's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Vivimed Labs's financial position?


Financial Position Analysis

Vivimed Labs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Vivimed Labs's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Vivimed Labs's level of debt (103.5%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (145% vs 103.5% today).

Debt is not well covered by operating cash flow (2.2%, less than 20% of total debt).

Interest payments on debt are not well covered by earnings (EBIT is 1.4x annual interest expense, ideally 3x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.3x debt.


Next Steps

Dividend

What is Vivimed Labs's current dividend yield, its reliability and sustainability?

2.68%

Current Dividend Yield


Dividend Yield and Payments Analysis

Vivimed Labs's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.65%).

Vivimed Labs's dividend is above the markets top 25% of dividend payers in India (2.64%).

Dividends per share have been volatile in the past 10 years (annual drop of over 20%).

Dividends per share have increased over the past 10 years.


Current Payout to Shareholders

Dividends paid are thoroughly covered by earnings (11.8x coverage).


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Vivimed Labs's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

Santosh Varalwar (57yo)

0.0yrs

Tenure

₹6,000,004

Compensation

Mr. Santosh Varalwar has been the Managing Director of Vivimed Labs Limited since January 27, 2004 and has been its Executive Director since November 09, 1989. Mr. Varalwar served as Chief Executive Office ...


CEO Compensation Analysis

Santosh's remuneration is higher than average for companies of similar size in India.

Santosh's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

0.8yrs

Average Tenure

57yo

Average Age

The average tenure for the Vivimed Labs management team is less than 2 years, this suggests a new team.


Board Age and Tenure

11.6yrs

Average Tenure

58.5yo

Average Age

The average tenure for the Vivimed Labs board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Santosh Varalwar (57yo)

    MD & Executive Director

    • Tenure: 0.0yrs
    • Compensation: ₹6.00m
  • Manohar Varalwar (82yo)

    Whole Time Director

    • Tenure: 24.8yrs
    • Compensation: ₹6.00m
  • Sandeep Varalwar (50yo)

    Whole Time Director

    • Tenure: 11.6yrs
    • Compensation: ₹6.00m
  • Srirambatla Raghunandan (59yo)

    CFO & Whole-Time Director

    • Tenure: 11.6yrs
    • Compensation: ₹5.00m
  • Amarjit Bhatia (55yo)

    Advisor of Vivimed Group

    • Tenure: 3.3yrs
    • Compensation: ₹4.38m
  • Snehashree Joshi

    Assistant Compant Secretary

    • Tenure: 0.0yrs
  • Yugandhar Kopparthi

    Compliance Officer & Company Secretary

    • Tenure: 0.0yrs

Board Members

  • Santosh Varalwar (57yo)

    MD & Executive Director

    • Tenure: 0.0yrs
    • Compensation: ₹6.00m
  • Subhash Varalwar (71yo)

    Non-Executive Director

    • Tenure: 29.8yrs
    • Compensation: ₹6.00m
  • Manohar Varalwar (82yo)

    Whole Time Director

    • Tenure: 24.8yrs
    • Compensation: ₹6.00m
  • Mamidpalli Rao (75yo)

    Chairman

    • Tenure: 0.0yrs
    • Compensation: ₹400.00k
  • Nixon Patel (58yo)

    Non-Executive Independent Director

    • Tenure: 9.2yrs
    • Compensation: ₹50.00k
  • Sandeep Varalwar (50yo)

    Whole Time Director

    • Tenure: 11.6yrs
    • Compensation: ₹6.00m
  • Srirambatla Raghunandan (59yo)

    CFO & Whole-Time Director

    • Tenure: 11.6yrs
    • Compensation: ₹5.00m
  • Umanath Varahabhotla (57yo)

    Independent Director

    • Tenure: 4.4yrs
    • Compensation: ₹250.00k

Company Information

Vivimed Labs Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vivimed Labs Limited
  • Ticker: 532660
  • Exchange: BSE
  • Founded: 1988
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹1.240b
  • Shares outstanding: 82.91m
  • Website: https://www.vivimedlabs.com

Number of Employees


Location

  • Vivimed Labs Limited
  • North End
  • Road No.2
  • Hyderabad
  • Andhra Pradesh
  • 500034
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
532660BSE (Mumbai Stock Exchange)INR2ININRInvalid date
532660BSE (Mumbai Stock Exchange)YesEquity SharesININRAug 2005
VIVIMEDLABNSEI (National Stock Exchange of India)YesEquity SharesININRAug 2005

Biography

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells specialty chemicals, dyes, and pharmaceutical ingredients in India, Mexico, Spain, and Hungary. It operates through three segmen ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/24 12:48
End of Day Share Price2019/08/23 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.